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Professor Pangloss and the Pangenome: DoesStaphylococcus aureus
Have the Best of All Possible Worlds?
In Voltaire’s 1759 novel Candide, the eponymous hero is
indoctrinated by his tutor, Professor Pangloss, to believe that
“everything is for the best in the best of all possible worlds.” In this
issue of the Journal, Long and colleagues (pp. 1127–1137) present a
meticulous and detailed analysis of whole genome sequencing data
of 1,382 isolates of Staphylococcus aureus from 246 children with
cystic fibrosis (CF), attending five U.S. care centers (1). The authors
suggest that S. aureus, through access to an open pangenome (the
collective genetic content of all isolates), develops persistent
genotypes, well adapted to the CF lung. For S. aureus, this may
indeed be “the best of all possible worlds.” The authors offer us
some intriguing insights into how S. aureus achieves this and the
implications this may have for the patient with CF.
In the first account of CF, Dorothy Andersen described
“. . . plugging of the lumens of most if not all of the bronchi with
tenacious, greenish-gray mucopurulent material . . .” (2). We
now know that these appearances result from dysfunction of the
CF transmembrane conductance regulator, leading to viscid
respiratory secretions, failure of the mucociliary escalator, bacterial
infection, and bronchiectasis (3). In a subsequent article (4),
Andersen described the microbiology of CF as, “Cultures taken
early in the course of the disease grow S. aureus hemolyticus in
nearly every case. . . .” Contemporary registry data support the high
prevalence of S. aureus early in life, but suggest that the organism is
present in over half of individuals with CF well into the fourth
decade (5). Long and colleagues describe some of the secrets behind
the organism’s remarkable longevity in the CF airway.
Almost half of the 246 children studied were infected with
multiple, coexisting S. aureus lineages, often with different antibiotic
susceptibility profiles. The authors show that these infections were
more often concurrent than they were sequential. Multiple lineages
of S. aureus do not primarily arise from hypermutation of resident
organisms in the CF airway—mutation rates in this study were
comparable to other patient groups. Mutations in the agrA and rsbU
transcriptional regulators, well recognized as important mediators of
the acute–chronic transition in S. aureus, were common in S. aureus
isolates in this study and were confirmed to modulate virulence
through altered protease production and hemolysis.
But the ability to interrogate relationships between pathogen
genotype and patient history in this large cohort adds interesting
new detail to the picture of how persistent infection is established.
Mutations in thyA, which confer resistance to trimethoprim-
sulfamethoxazole, were associated with the patient being treated
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with this specific antimicrobial. In addition to trimethoprim-
sulfamethoxazole resistance, thyA mutation has been associated
with a switch to the small colony variant phenotype, which results
in generally increased antibiotic tolerance and in vivo persistence
(6). In contrast, rpoB, mutations in which confer resistance to
rifamycin, had the strongest signature of natural selection in the
study, despite the fact that only a minority of patients with de novo
mutations in this gene were exposed to this drug. Mutations in
rpoB have previously been associated with S. aureus persistence
through increased tolerance of mammalian antimicrobial peptides
(7). Thus, antibiotic-mediated selection for resistance may also
confer a general survival advantage in the CF airway (thyA), and,
conversely, selection for increased survival in the CF airway may
have the byproduct of resistance to an antibiotic (rpoB) that the
organism has not yet encountered.
The data presented by Long and colleagues raise an important
question about microbial ecology: How spatially structured are the
diverse S. aureus populations within the lungs of people with CF?
There is good evidence for spatial structuring of microbial
populations across the CF lungs (8), and the degree of intermixing
(or not) of S. aureus subpopulations will be key in understanding
the selection of persisting strains. Do different strains of S. aureus
coexist side by side or do they rarely meet? This may also resolve
some open questions about how S. aureus lives in CF lungs: are
some or all populations intracellular (9), associated with the
bronchiolar tissue surface (10), or living within mucus in the
bronchial lumen (11)?
This study not only provides insights into the lifestyle of
S. aureus but also suggests practical conclusions for infection
prevention and control. Using granular molecular epidemiology,
Long and colleagues provide detailed information on 11 paired
cases in which “strain sharing” between individuals with CF is
likely (isolates were separated by <36 variants). Strain sharing may
be explained by sibling pairs (5 pairs). However, for several pairs
attending different CF centers, acquisition of the organism
appeared after contact with a single care provider who moved from
one CF center to another. Around one-third of the U.S. population
will carry S. aureus in the nasopharynx (12). These data underscore
the need for scrupulous adherence to infection prevention and
control guidelines (13).
The data on antimicrobial resistance are important for clinical
practice. In the United Kingdom, but not in the United States (14),
it is standard practice to use prophylactic antistaphylococcal
antibiotics in young infants with CF from diagnosis (15). As noted
above, children in this study could be infected simultaneously with
multiple, different S. aureus lineages. One individual might harbor
both methicillin-resistant S. aureus (MRSA) and sensitive strains.
Indeed, lineages could change from methicillin-resistant to
methicillin-sensitive over time. This suggests that culture and
sensitivity techniques, currently used in CF centers, may not be
sufficiently comprehensive for optimal treatment of MRSA. The
authors propose that routine laboratory tests might be developed to
characterize coexisting S. aureus lineages better, using either culture
or whole genome sequencing. Furthermore, long-term surveillance
may be necessary before successful eradication of MRSA can be
claimed. The STaph Aureus Resistance - Treat Or Observe (STAR-
too) trial of MRSA eradication (16) reported 82% eradication at 28
days, dropping to 54% at 84 days.
Finally, the authors suggest that new antimicrobial agents
might be designed to reduce the virulence of the organism without
exerting selective pressure for resistance, and such agents have been
proposed as useful “antibiotic adjuvants” (17). Voltaire’s novel
Candide contains an incident (based on historical fact) in which a
British Admiral is shot by firing squad “to encourage the others.”
Candide is a satire—it is plainly ridiculous to expect survivors to be
encouraged by the execution of one of their number—or is it? In
the field of antimicrobial resistance, the execution of bacteria, with
an antimicrobial, exerts selective pressure and “encourages”
bacterial resistance. Long and colleagues have described an
organism exquisitely adapted for long-term survival in the CF
airway. New approaches are needed to combat S. aureus infection
as it enjoys “the best of all possible worlds.” n
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It’s Not Just a Smoking-related Disease: Outdoor Pollution May
Increase Risk of Chronic Obstructive Pulmonary Disease
It is well accepted that air pollution exacerbates existing respiratory
diseases in adults, including asthma and chronic obstructive
pulmonary disease (COPD). It is less clear if cumulative exposure
to air pollution increases the incidence of new obstructive lung
diseases in adults. In this issue of the Journal, Shin and colleagues
(pp. 1138–1148) present a population-based study of all 5 million
adults living in the Canadian province of Ontario who were free of
asthma or COPD diagnosis in 2001 (1). During the 15-year study
follow-up period, over 340,000 incident cases of COPD and over
218,000 incident cases of asthma were identified. Using a 3-year
average of air pollution exposure with a 1-year lag, the authors
found that multiple outdoor pollutants, including fine particulate
matter (PM2.5), nitrogen dioxide (NO2), and ozone (O3), were
associated with greater COPD incidence, which is defined as a
COPD hospitalization or at least three physician claims for COPD
within 2 years. In contrast, there were no associations between
exposure to these pollutants and new adult-onset asthma.
Ontario is a large contiguous geographic area that includes a large
metropolitan area and more rural areas with sufficient variability in the
long-term exposure to these pollutants to examine associations with
asthma and COPD incidence, even at the relatively low pollution
concentrations in Canada. A major strength of this population-based
cohort study is that it included allOntarians with minimal concern for
selection bias because everyone is eligible for the publicly funded
health plan. However, the use of administrative claims data has the
important limitation that the authors could not directly adjust for
individual-level habits such as tobacco use, which is the number one
cause of COPD. The authors attempted to address this limitation by
adjusting for individual-level comorbidities, fine-scale neighborhood
characteristics, and indirectly adjusted for smoking and obesity using
an auxiliary dataset. The findings for COPD were robust to
adjustment for these potential confounding variables. Interestingly,
healthier adults (those without comorbidities and those who were
younger at baseline) had a larger relative risk of COPD in association
with pollution than those who had more comorbidities or were older.
As in other research on the health effects of pollution, residents in
neighborhoods of lower socioeconomic position had a heightened risk
of COPD incidence in association with PM2.5 compared with those in
more privileged neighborhoods.
The authors examined the shape of exposure–response
relationships and found “supralinear functions” for PM2.5, O3, and the
redox-weighted oxidative potential of O2 and NO2, meaning that the
exposure–response relationship for COPD incidence was steeper at
lower exposure concentrations (,10 mg/m3 PM2.5 and ,40 ppb O3)
and less steep at higher exposure concentrations. This pattern of
greater health effects per increment of pollution at the lower range of
exposure has been observed for other health effects of PM2.5 and O3
exposure, including mortality (2). For NO2 exposure, there appeared
to be a threshold effect with increasing risk for COPD only above 25
ppb. The authors importantly highlight that these adverse effects were
observed for concentrations well below the current U.S. national
ambient air quality standard for PM2.5, O3, and NO2. Several recent
reports have concluded that despite the strong plausibility that
outdoor pollution causes COPD (based in part on the compelling
evidence for tobacco and indoor biomass smoke), the evidence thus
far has been deemed insufficient to determine causality (3–5). This
study provides compelling evidence that long-term exposure to higher
concentrations of ambient pollution increases the incidence of COPD.
In contrast, results for adult-onset asthma were null. There are
several possible reasons for these null results: 1) there is truly no
effect of air pollution during adulthood on adult-onset asthma at
the pollution concentrations observed; 2) sampling error, which
randomly resulted in variation from the true population effect; or
3) bias was present in the study that only (or more severely)
impacted the asthma analysis and not the COPD analysis. We
discuss each of these below.
Air pollution exposure may not increase the risk of asthma in
adults at the concentrations observed in this study. A recent
American Thoracic Society workshop concluded that traffic-related
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